EP1844006A2 - Taurine synthesis, production and utility as a medicine - Google Patents

Taurine synthesis, production and utility as a medicine

Info

Publication number
EP1844006A2
EP1844006A2 EP05818935A EP05818935A EP1844006A2 EP 1844006 A2 EP1844006 A2 EP 1844006A2 EP 05818935 A EP05818935 A EP 05818935A EP 05818935 A EP05818935 A EP 05818935A EP 1844006 A2 EP1844006 A2 EP 1844006A2
Authority
EP
European Patent Office
Prior art keywords
effective
concentrations
prevention
combinations
controlling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05818935A
Other languages
German (de)
French (fr)
Inventor
Magd Ahmed Kotb Abdalla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Magd Ahmed Kotb Abdalla
Original Assignee
Magd Ahmed Kotb Abdalla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magd Ahmed Kotb Abdalla filed Critical Magd Ahmed Kotb Abdalla
Publication of EP1844006A2 publication Critical patent/EP1844006A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton

Definitions

  • bile salts the conjugate bases of bile acids.
  • the major bile salts are synthesized and secreted by as glycine or taurine conjugates.
  • Taurine is a degradation product of cysteine. Taurine (2-aminoethyl sulphonic acid) is a component of bile. It combines with cholic acid to form taurocholic acid. Cholic acid is the metabolic fate of cholesterol. The formation of cholic acid involves a pathway involving several hydroxylations and oxidation reactions. All water soluble vitamins participate in these reactions.
  • Taurine lowers cholesterol, and this action is potentiated by the presence of water soluble vitamins.
  • Taurine is effective in lowering hypercholesterolaemia, hypertriglyceridaemia and all lipid associated disorders as in cholestasis or nephrotic syndrome, etc.. also it is effective in any type of familial or idiopathic or acquired lipid disorder. Taurine is cardioprotective. ( Taurine is also effective in gall stone dissolution.
  • Taurine is safe, and effective in normalizing high cholesterol, low density lipoproteins, or very low density lipoproteins.
  • Taurine is also essential for stabilizing brain cells against changes in blood osmolality, and in conversion of serotonin to endorphins. It is effective in depression, migraine, headache, Alzheimer disease, and in psychiatric and neurological diseases.
  • lipids, lipoproteins, cholesterol, and hypercholestrolaemia associated diseases, psychiatric and neurological diseases and in gall stone dissolution the following singly or combined are effective: a. Taurine b. Cysteine and/or acetyl cysteine, c. All water soluble vitamins.
  • the "a”, or “b” or “c” or as “a+b”, or “a+c”, or “b+c” or, “a+ b+ c” in any and all concentrations and combinations are effective in prevention and controlling all hypercholestrolaemias, hypertriglycerdaemias, and all and any lipid and lipoprotein disorders.
  • the “a”, or “b” or “c” or as “a+b”, or “a+c”, or “b+c” or, “a+ b+ c” in any and all concentrations and combinations are effective in prevention and controlling cholestasis disorders of any aetiology. viii.
  • the "a”, or “b” or “c” or as “a+b”, or “a+c”, or “b+c” or, “a+ b+ c” in any and all concentrations and combinations are effective in prevention and controlling steatosis of liver and steatohepatitis disorders of any aetiology.
  • the “a”, or “b” or “c” or as “a+b”, or “a+c”, or “b+c” or, “a+ b+ c” in any and all concentrations and combinations are effective in prevention, dissolution and controlling gall stone diseases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The quantitatively most important pathway for the excretion of cholesterol in mammals is the formation of bile salts (the conjugate bases of bile acids). The major bile salts are synthesized and secreted by as glycine or taurine conjugates. Taurine (2 aminoethyl sulphonic acid) is naturally produced by the liver cells and central nervous system cells, it is neuroprotective and is a cholesterol lowering agent with virtually no recorded side effects.

Description

Taurine synthesis, production and utility as a medicine
Technical Field:
1. Medicine
Background Art:
The quantitatively most important pathway for the excretion of cholesterol in mammals is the formation of bile salts (the conjugate bases of bile acids). The major bile salts are synthesized and secreted by as glycine or taurine conjugates.
Disclosure of Invention:
Taurine is a degradation product of cysteine. Taurine (2-aminoethyl sulphonic acid) is a component of bile. It combines with cholic acid to form taurocholic acid. Cholic acid is the metabolic fate of cholesterol. The formation of cholic acid involves a pathway involving several hydroxylations and oxidation reactions. All water soluble vitamins participate in these reactions.
Taurine lowers cholesterol, and this action is potentiated by the presence of water soluble vitamins.
Taurine is effective in lowering hypercholesterolaemia, hypertriglyceridaemia and all lipid associated disorders as in cholestasis or nephrotic syndrome, etc.. also it is effective in any type of familial or idiopathic or acquired lipid disorder. Taurine is cardioprotective. ( Taurine is also effective in gall stone dissolution.
Taurine is safe, and effective in normalizing high cholesterol, low density lipoproteins, or very low density lipoproteins.
Taurine is also essential for stabilizing brain cells against changes in blood osmolality, and in conversion of serotonin to endorphins. It is effective in depression, migraine, headache, Alzheimer disease, and in psychiatric and neurological diseases. The Novel Idea:
To control: blood levels of lipids, lipoproteins, cholesterol, and hypercholestrolaemia associated diseases, psychiatric and neurological diseases and in gall stone dissolution, the following singly or combined are effective: a. Taurine b. Cysteine and/or acetyl cysteine, c. All water soluble vitamins.
Detailed Description of the Requested Patent: a. Taurine manufactured by all known ways as sulphonation of ethyl alcohol followed by substitution reaction at C2 or recombinant DNA technology to produce 2 aminoethyl sulphonic acid or any possible way, or by the use probiotics to promote the use of intestinal bacterial flora to reclaim taurine from the previously liver formed taurocholic acid and taurochenodexoycholic acid etc.... b. Acetyl cysteine is manufactured by all known ways. c. Water soluble vitamins are manufactured by all known ways.
Where:
i. All "a", "b" and "c" are effective if given as "a", or "b" or "c" or as "a+b", or "a+c"; or "b+c" or, "a+ b+ c". ii. All "a", "b" and "c" are effective if given as "a", or "b" or "c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" when provided in oral or parenteral, or topical preparations. iii. All and any composition and any and all concentrations of "a", or "b" or "c" or as "a+b", or "a+c", or "b+c" or,
"a+ b+ c" are effective. iv. Taurine used comes in its acid form or acid salt or alkali salt or in any of its compounds, or forms. v. The "a", or "b" or "c" or as "a+b", or "a+c"5 or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling asthersclerosis and cardiac diseases. vi. The "a", or "b" or "c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling all hypercholestrolaemias, hypertriglycerdaemias, and all and any lipid and lipoprotein disorders. vii. The "a", or "b" or "c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling cholestasis disorders of any aetiology. viii. The "a", or "b" or "c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling steatosis of liver and steatohepatitis disorders of any aetiology. ix. The "a", or "b" or "c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention, dissolution and controlling gall stone diseases. x. The "a", or "b" or "c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling all psychiatric and all neurologic diseases.

Claims

Claims:I claim that:a. Taurine manufactured by all known ways as sulphonation of ethyl alcohol followed by substitution reaction at C2 or recombinant DNA technology to produce 2 aminoethyl sulphonic acid or any possible way, or by the use probiotics to promote the use of intestinal bacterial flora to reclaim taurine from the previously liver formed taurocholic acid and taurochenodexoycholic acid etc.... b. Acetyl cysteine is manufactured by all known ways. c. Water soluble vitamins are manufactured by all known ways.Where:
1. All "a", "b" and "c"- are effective if given as "a", or "b" or "c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c".
2. All "a", "b" and "c" are effective if given as "a", or "b" or "c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" when provided in oral or parenteral, topical preparations.
3. All and any composition and any and all concentrations of "a", or "b" or "c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" are effective.
4. Taurine used comes in its acid form or acid salt or alkali salt or in any of its compounds, forms or shapes.
5. The "a", or "b" or "c" or as "a+b", or αa+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling asthersclerosis and cardiac diseases.
6. The "a", or "b" or "c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling all hypercholestrolaemias, hypertriglycerdaemias, and all and any lipid and lipoprotein disorders.
7. The "a", or "b" or "c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling cholestasis disorders of any aetiology.
8. The "a", or "b" or "c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling steatosis of liver and steatohepatitis disorders of any aetiology.
9. The "a", or "b" or "c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling gall stone diseases.
10. The "a", or "b" or "c" or as "a+b", or "a+c", or "b+c" or, "a+ b+ c" in any and all concentrations and combinations are effective in prevention and controlling all psychiatric and all neurologic diseases.
EP05818935A 2005-01-05 2005-12-31 Taurine synthesis, production and utility as a medicine Withdrawn EP1844006A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EG2005010013 2005-01-05
PCT/EG2005/000044 WO2006072259A2 (en) 2005-01-05 2005-12-31 Taurine synthesis, production and utility as a medicine

Publications (1)

Publication Number Publication Date
EP1844006A2 true EP1844006A2 (en) 2007-10-17

Family

ID=36647837

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05818935A Withdrawn EP1844006A2 (en) 2005-01-05 2005-12-31 Taurine synthesis, production and utility as a medicine

Country Status (15)

Country Link
EP (1) EP1844006A2 (en)
JP (1) JP2008526789A (en)
KR (1) KR20070091198A (en)
CN (1) CN101146767A (en)
AP (1) AP2007004084A0 (en)
AU (1) AU2005324199A1 (en)
BR (1) BRPI0519606A2 (en)
CA (1) CA2593563A1 (en)
EA (1) EA200701434A1 (en)
IL (1) IL184221A0 (en)
MA (1) MA29238B1 (en)
MX (1) MX2007008196A (en)
NO (1) NO20074937A (en)
TN (1) TNSN07226A1 (en)
WO (1) WO2006072259A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20130590T1 (en) 2007-11-30 2013-08-31 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
CN103382170B (en) * 2012-10-25 2015-04-08 潜江永安药业股份有限公司 Preparation method for taurine
CN106728405A (en) * 2016-11-15 2017-05-31 陈思文 A kind of taurine and water soluble tea polyphenol compound and preparation method and application

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58140017A (en) * 1981-12-22 1983-08-19 Junichi Azuma Remedy for cardiac insufficiency
JPH08208464A (en) * 1994-12-02 1996-08-13 Taisho Pharmaceut Co Ltd Treatment and prevention drug for hyperlipidemia
US6184227B1 (en) * 1995-07-21 2001-02-06 Savvipharm Inc. Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
SE9601395D0 (en) * 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 1
GB9722361D0 (en) * 1997-10-24 1997-12-17 Pharma Nord Uk Ltd Pharmaceutical formulation for treating liver disorders
NZ527924A (en) * 1999-01-29 2005-01-28 Mars Uk Ltd Antioxidant compositions and methods for companion animals
AU8003800A (en) * 1999-10-08 2001-04-23 Joyce Corinne Bechthold Methods and compositions for treating neurobehavioral disorders
CN1340502A (en) * 2000-06-30 2002-03-20 张永春 Process for preparing taurine zinc
CN1268733C (en) * 2004-07-20 2006-08-09 刘辉 Taurine functional beer and its producing process

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006072259A3 *

Also Published As

Publication number Publication date
CN101146767A (en) 2008-03-19
KR20070091198A (en) 2007-09-07
AP2007004084A0 (en) 2007-08-31
CA2593563A1 (en) 2006-07-13
EA200701434A1 (en) 2008-10-30
WO2006072259A2 (en) 2006-07-13
MX2007008196A (en) 2008-02-22
JP2008526789A (en) 2008-07-24
TNSN07226A1 (en) 2008-11-21
BRPI0519606A2 (en) 2009-02-25
NO20074937A (en) 2007-09-28
MA29238B1 (en) 2008-02-01
IL184221A0 (en) 2008-12-29
AU2005324199A1 (en) 2006-07-13
WO2006072259A3 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
TW589186B (en) Ascorbyl-phosphoryl-cholesterol
IE53432B1 (en) A method for preparing ganglioside derivatives and use thereof in pharmaceutical compositions
CN101098879B (en) Novel Selenic Acids and Derivatives and Applications in Nutraceuticals, Cosmetics and Pharmaceuticals
JP2014185163A (en) Therapies for cancer using isotopically substituted lysine
EP0631779A1 (en) Use of esters of L-carnitine and acyl L-carnitine with hydroxyacids for producing pharmaceutical compositions for treating dermatoses
CN111971290A (en) Glucosamine derivatives for preventing or treating joint diseases
JP2002533421A (en) Disease treatment using NAALADase inhibitor
JPWO2005033123A1 (en) Stable vitamin B6 derivative
EP4678629A1 (en) Ionizable lipid molecule, preparation method therefor and use thereof
EP1844006A2 (en) Taurine synthesis, production and utility as a medicine
JP5671483B2 (en) Pigmentation preventing or improving agent
CA3202047A1 (en) Fucosyltransferase specific inhibition using fucose mimetics
CN120659771A (en) Amino lipid compound, preparation method and application thereof
US6451761B1 (en) N′N′-dichlorinated omega-amino acids and uses thereof
FR2989087A1 (en) NOVEL OLIGOSACCHARIDE COMPOUNDS AND THEIR COSMETIC USE
JP2020514307A (en) Compound and method of use
FR2894968A1 (en) NOVEL CHOLEST-4-EN-3-ONE OXIME DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND PROCESS FOR PREPARING THE SAME
EP2072494B1 (en) Cosmetic and pharmaceutical compositions
WO2011030727A1 (en) External preparation containing pantethine phosphate ester
EP1234816B1 (en) Scyphostatin analogues as SMase inhibitors
CN109320577B (en) Fusidic acid derivative with antitumor activity and synthesis and preparation method thereof
KR20030003952A (en) Compositions for the prevention and treatment of inflammatory skin diseases
CN105102466B (en) The sugared dendroid cluster compound of inhibitor as BACE-1
US20160228489A1 (en) Pharmaceutical composition for the prevention and the treatment of degenerative skin disorders especially caused by ionizing radiations
CA3165408C (en) Dendrimers having thiophosphoramidate patterns and derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070731

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

R17D Deferred search report published (corrected)

Effective date: 20071004

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1103070

Country of ref document: HK

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1105119

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/10 20060101ALI20080128BHEP

Ipc: A61K 31/145 20060101ALI20080128BHEP

Ipc: C07C 303/02 20060101AFI20060720BHEP

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20080623

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081103

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1103070

Country of ref document: HK

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1105119

Country of ref document: HK